Results 91 to 100 of about 1,168 (140)
TaxReasoning: Benchmarking Knowledge-Intensive Mathematical Reasoning with Evolving Tax Laws [PDF]
Chen, Jiaoyan +10 more
core
A Beacon Trying to Signal Heading: The Ninth Circuit Interprets the California Whistleblower Protection Act in Killgore v. SpecPro Professional Services, LLC [PDF]
Memari, Naseem
core +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Days of AMNuBIH and IANUBIH, Sarajevo, December 4th, 2021
International Journal on Biomedicine and Healthcare, 2021Days of Academy of Medical Sciences of Bosnia and Herzegovina (AMNuBiH) this year was organized together with International Academy of Sciences and Arts in Bosnia and Herzegovina (IANUBIH) in Sarajevo, Bosnia and Herzegovina on December 4th, 2021.
I. Masic
semanticscholar +1 more source
Journal of Clinical Oncology, 2021
4550 Background: Considering the synergistic/additive effect of PD-1 blockade and angiogenesis inhibition, we conducted an open-label, multi-center phase II study of camrelizumab (an anti-PD-1 antibody) plus famitinib (a TKI against VEGFR-2, PDGFR, c-kit,
Y. Qu +14 more
semanticscholar +1 more source
4550 Background: Considering the synergistic/additive effect of PD-1 blockade and angiogenesis inhibition, we conducted an open-label, multi-center phase II study of camrelizumab (an anti-PD-1 antibody) plus famitinib (a TKI against VEGFR-2, PDGFR, c-kit,
Y. Qu +14 more
semanticscholar +1 more source
Journal of the American Society of Nephrology, 2021
Background: Catheter dysfunction (CD) is a frequent complication during the provision of hemodialysis. Thrombolytic agents (i.e. alteplase) are the mainstay for resolving CD, however, alteplase usage has increased 16% (~$440,000CAD) annually in the ...
Jason T. Bau +5 more
semanticscholar +1 more source
Background: Catheter dysfunction (CD) is a frequent complication during the provision of hemodialysis. Thrombolytic agents (i.e. alteplase) are the mainstay for resolving CD, however, alteplase usage has increased 16% (~$440,000CAD) annually in the ...
Jason T. Bau +5 more
semanticscholar +1 more source
Journal of the American Society of Nephrology, 2021
Background: Catheter dysfunction (CD) is a frequent complication during the provision of hemodialysis. Thrombolytic agents (i.e. alteplase) are the mainstay for resolving CD, however, alteplase usage has increased 16% (~$440,000CAD) annually in the ...
Sonoo Mizuiri +10 more
semanticscholar +1 more source
Background: Catheter dysfunction (CD) is a frequent complication during the provision of hemodialysis. Thrombolytic agents (i.e. alteplase) are the mainstay for resolving CD, however, alteplase usage has increased 16% (~$440,000CAD) annually in the ...
Sonoo Mizuiri +10 more
semanticscholar +1 more source
Monitoring of Intradialytic Sleep Apnea in Hemodialysis Patients
Journal of the American Society of Nephrology, 2021Background: Catheter dysfunction (CD) is a frequent complication during the provision of hemodialysis. Thrombolytic agents (i.e. alteplase) are the mainstay for resolving CD, however, alteplase usage has increased 16% (~$440,000CAD) annually in the ...
Paulo Paneque Galuzio +5 more
semanticscholar +1 more source
Clinical Trials, 2021
Introduction: Selpercatinib, approved by FDA in May 2020 is a highly selective and potent RET inhibitor which has demonstrated antitumor activity in patients (pts) with RET-altered non-small-cell lung cancer and thyroid cancer.
T. Bauer +7 more
semanticscholar +1 more source
Introduction: Selpercatinib, approved by FDA in May 2020 is a highly selective and potent RET inhibitor which has demonstrated antitumor activity in patients (pts) with RET-altered non-small-cell lung cancer and thyroid cancer.
T. Bauer +7 more
semanticscholar +1 more source